Apatinib is a novel receptor tyrosine kinase (RTK) inhibitor that selectively competes for the vascular endothelial growth factor receptor 2 (VEGFR-2) ATP binding site, blocking downstream signaling and inhibiting tumor angiogenesis [11, 12]. This evidence concerns the gene KDR and neoplasm.